| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17460441.2.1.87 |
| P698 | PubMed publication ID | 23496039 |
| P2093 | author name string | Romano Silvestri | |
| Giuseppe La Regina | |||
| Antonia Coluccia | |||
| Rino Ragno | |||
| P2860 | cites work | Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase | Q27628304 |
| Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors | Q27635069 | ||
| Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance | Q27766086 | ||
| Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor | Q28323582 | ||
| Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives | Q28334841 | ||
| Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors | Q28367590 | ||
| Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase | Q28368023 | ||
| Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations | Q28378285 | ||
| L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase | Q28378789 | ||
| Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor | Q29547710 | ||
| A computational procedure for determining energetically favorable binding sites on biologically important macromolecules | Q30406755 | ||
| Antimycobacterial pyrroles: synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies. | Q31407411 | ||
| Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. | Q31454187 | ||
| Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel | Q33824632 | ||
| Estimation of aqueous solubility of chemical compounds using E-state indices | Q33843973 | ||
| Highlights in the development of new antiviral agents | Q33961840 | ||
| A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 | Q33979107 | ||
| ??? | Q28297986 | ||
| Genome organization and transactivation of the human immunodeficiency virus type 2. | Q34048704 | ||
| Emerging drug targets for antiretroviral therapy | Q36237524 | ||
| Nucleoside and nucleotide inhibitors of HIV-1 replication. | Q36359017 | ||
| Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. | Q39267636 | ||
| Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. | Q40538441 | ||
| 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies | Q40582883 | ||
| Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C | Q40592867 | ||
| Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies | Q40644238 | ||
| Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1 reverse transcriptase. | Q40740603 | ||
| 5H-pyrrolo[1,2-b] [1,2,5]benzothiadiazepines (PBTDs): a novel class of non-nucleoside reverse transcriptase inhibitors. | Q41193730 | ||
| 2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones | Q41238181 | ||
| Design, synthesis and QSAR studies on N-aryl heteroarylisopropanolamines, a new class of non-peptidic HIV-1 protease inhibitors | Q44022775 | ||
| Therapies. Raising the limits | Q44044876 | ||
| HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies | Q45212830 | ||
| Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives | Q45212833 | ||
| Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. | Q52264578 | ||
| Design, Molecular Modeling, Synthesis, and Anti-HIV-1 Activity of New Indolyl Aryl Sulfones. Novel Derivatives of the Indole-2-carboxamide | Q57266181 | ||
| Comparative Molecular Field Analysis Using GRID Force-Field and GOLPE Variable Selection Methods in a Study of Inhibitors of Glycogen Phosphorylase b | Q58137179 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 87-114 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Expert Opinion on Drug Discovery | Q5421204 |
| P1476 | title | Indolyl aryl sulphones as HIV-1 reverse transcriptase inhibitors: docking and 3D QSAR studies | |
| P478 | volume | 2 |
Search more.